Cargando…
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
The administration of many cancer drugs is tailored to genetic tests. Some genomic events, e.g., alterations of EGFR or BRAF oncogenes, result in the conformational change of the corresponding proteins and call for the use of mutation-specific compounds. Other genetic perturbations, e.g., HER2 ampli...
Autores principales: | Aleksakhina, Svetlana N., Imyanitov, Evgeny N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536080/ https://www.ncbi.nlm.nih.gov/pubmed/34681592 http://dx.doi.org/10.3390/ijms222010931 |
Ejemplares similares
-
Hereditary cancer syndromes
por: Imyanitov, Evgeny N, et al.
Publicado: (2023) -
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
por: Orlova, Kristina V., et al.
Publicado: (2019) -
Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019) -
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
por: Imyanitov, Evgeny N.
Publicado: (2021) -
Drug therapy for hereditary cancers
por: Imyanitov, Evgeny N, et al.
Publicado: (2011)